🇺🇸 FDA
Patent

US 11920134

Compositions and methods for inhibiting expression of RRM2 genes

granted A61KA61K48/00A61P

Quick answer

US patent 11920134 (Compositions and methods for inhibiting expression of RRM2 genes) held by Arrowhead Pharmaceuticals, Inc. expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K48/00, A61P, A61P35/00